Article Figures & Data
Figures
- Fig. 1.
Mean percentage of change from base line in the number of polyps; bars, ±SE. At 9 months, the polyp number in the group given rofecoxib decreased by 6.8% from the baseline values, whereas in the group of placebo, it increased by 3.1%. The 9.9% difference between the rofecoxib and placebo groups was statistically significant (P = 0.004).
- Fig. 2.
Mean percentage of change from base line in the size of polyps; bars, ±SE. At 9 months, the group given rofecoxib was associated with a significant reduction from the baseline in the size of rectal polyps as compared with the placebo group (−16.2% versus 1.5%; P < 0.001).
Tables
- Table 1
Schedule of the study
Months Baseline Treatment period Post-treatment period 1 2 3 4 5 6 7 8 9 10 11 12 Discontinuation Colonoscopy X X X X X X Gastroduodenoscopy X X X X Physical examination X X X X X X X X X X X X X X Blood pressure, body weight X X X X X X X X X Laboratory tests X X X X X X X X X - Table 2
Baseline characteristics of the patients with familial adenomatous polyposisa
Characteristic Placebo n = 9 Rofecoxib n = 12 Age yr. 33.6 ± 14.8 32.3 ± 11.2 Gender no. (%) Male 4 (44.4) 7 (58.3) Female 5 (55.6) 5 (41.7) Height cm 161.2 ± 7.2 162.7 ± 4.5 Weight kg 57.7 ± 12.9 51.8 ± 7.4 Surgical status no. (%) Intact colon 3 (33.3) 5 (41.7) Colectomy 6 (66.7) 7 (58.3) No. of polyps 7.2 ± 3.3 8.0 ± 4.5 Polyp size mm 3.3 ± 0.8 3.0 ± 0.7 -
a Plus-minus values are means ± SD.
-
Volume 9, Issue 13
